Quchang Ouyang

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 267 citations

Medicine, Oncology, Pharmacology +14

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Quchang Ouyang, Tao Sun et al. · Nature Medicine · 2024 · 112 citations

Medicine, Oncology, Pharmacology +14

Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

Min Yan, Li Bian, Xichun Hu et al. · Translational Breast Cancer Research · 2020 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17

The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial

Qiao Li, Jiaxuan Liu, Qingyuan Zhang et al. · Nature Communications · 2024 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17